Author: [email protected]

BOULDER, Colo.–(BUSINESS WIRE)–Aug. 3, 2022– Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present at the Canaccord Genuity 42nd Annual Growth Conference being held August 8-11, 2022.

Biodesix to Present Data at IASLC 2022 World Conference Demonstrating that the VeriStrat® Test is Predictive of Progression Free Survival and Overall Survival in Patients with Low or Negative PD-L1 Treated with Immune Checkpoint Inhibitors New data emphasizes the utility of the VeriStrat® Proteomic Test to identify patients likely to benefit from Immune Checkpoint Inhibitors

BOULDER, Colo.–(BUSINESS WIRE)–Jul. 19, 2022– Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus on lung disease, today announced that it will release financial results for the second quarter ended June 30, 2022 before the open of trading on Thursday, August 4. Biodesix’s management will host a conference call and webcast to discuss its financial results…

Solution adds proteomic analysis of blood-based biomarkers to Philips Lung Cancer Orchestrator to better assess the risk of lung nodule malignancy, enhancing decision-making for diagnosis and treatment

BOULDER, Colo.— (BUSINESS WIRE)— June 7, 2022— Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced that WPS Government Health Administrators, the Medicare Administrative Contractor with jurisdiction for Biodesix’s De Soto, Kansas laboratory, has provided coverage for the Nodify CDT® lung nodule test.

Aim is to develop and commercialize new pipeline oncology biomarker assay in collaboration with Memorial Sloan Kettering Cancer Center and Bio-Rad, Inc.

BOULDER, Colo.–(BUSINESS WIRE)– Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present at the 42nd Annual William Blair Growth Stock Conference being held June 6-9, 2022 at the Lowes Chicago Hotel in Chicago, IL.

First quarter 2022 core Lung Diagnostic revenue of $4.6 million increased 17% over the comparable period in 2021;